Under the exclusive agreement with Eli Lilly and Company, Anima Biotech will use its technology platform for the discovery and development of translation inhibitors for several undisclosed target proteins.
According to the company, Anima’s Translation Control Platform is “strategically structured for collaborations with multiple pharma partners.” The technology combines “new biology with proprietary image analysis and high-performance big data software,” and is protected by five patents.
Lilly will be responsible for clinical development and any potential product commercialization.
Anima will receive $30m in upfront payments and $14m in research funding and is eligible to receive up to $1.05bn if it achieves all future development and commercial milestones.
Additionally, Anima is entitled to low- to mid-single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
Anima Biotech has not responded to a request for comment.